During the collaboration, Carmot will apply its proprietary lead-identification technology, Chemotype Evolution, to discover novel drug hits. Carmot and Genentech will work together to identify lead candidates, while
The companies will use avelumab, a PD-L1 checkpoint inhibitor, together with a platinum-based chemotherapy for women with locally advanced or metastatic disease with earlier untreated epithelial ovarian cancer.
The acceptance of the two NDAs, one for the intravenous formulation and one for oral capsules, indicates the applications are sufficiently complete to permit a substantive review by
Aprecia manufactures its products using its proprietary ZipDose technology platform, that utilizes three dimensional printing (3DP) to formulate fast melt pharmaceutical products, which incorporates significantly higher amounts of
All commercial manufacturing of RIZAPORT will take place at IntelGenx’ new state-of-the-art manufacturing facility in Canada. Full details of the financial terms of the agreement were not disclosed.
Zinbryta, which is being developed by Biogen and AbbVie, is a once-monthly, self-administered, subcutaneous injection. It has an immunomodulatory mechanism of action that regulates inflammation without depleting the
The funding represents an additional $5.5 million to BioCryst for the development of BCX4430 as a treatment for hemorrhagic fever viruses. The new total NIAID contract amount to
"We are thrilled to begin this collaboration with Dr. Plemper as we broaden our internal efforts to develop RSV non-fusion inhibitor compounds to complement BTA585, our fusion inhibitor
The antibody will be tested in the field of prevention of thrombosis. This is the twelfth therapeutic antibody based on MorphoSys’s technologies that Novartis is evaluating in clinical
This request for filing was based on clinical data from the phase 2/3 study AB10015, which was successful on its pre-specified primary endpoint at the interim analysis (192
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.